These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 14757690)

  • 1. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
    Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study.
    De Luca L; Sardella G; De Persio G; Petrolini A; Fedele F
    Acute Card Care; 2008; 10(2):93-9. PubMed ID: 18568571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis.
    Hong YJ; Jeong MH; Hwang SH; Yun NS; Lim SY; Lee SR; Hong SN; Kim KH; Park HW; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
    Int J Cardiol; 2007 Dec; 123(1):23-8. PubMed ID: 17289173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
    Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A
    Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.
    López-Mínguez JR; Nogales JM; González R; Palanco C; Doncel J; Vaello A; Giménez F; Morales A; Alonso R; Merchán A
    Cardiovasc Revasc Med; 2007; 8(3):175-82. PubMed ID: 17765647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
    Kim SS; Hong YJ; Jeong MH; Kim W; Kim HK; Ko JS; Lee MG; Sim DS; Park KH; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Song SJ; Cho DL; Kang JC
    Circ J; 2010 Mar; 74(3):442-8. PubMed ID: 20103970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE).
    Serruys PW; Wijns W; Sianos G; de Scheerder I; van den Heuvel PA; Rutsch W; Glogar HD; Macaya C; Materne PH; Veldhof S; Vonhausen H; Otto-Terlouw PC; van der Giessen WJ
    J Am Coll Cardiol; 2004 Aug; 44(3):528-37. PubMed ID: 15358015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.
    Degertekin M; Serruys PW; Foley DP; Tanabe K; Regar E; Vos J; Smits PC; van der Giessen WJ; van den Brand M; de Feyter P; Popma JJ
    Circulation; 2002 Sep; 106(13):1610-3. PubMed ID: 12270850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.
    Kim W; Jeong MH; Hong YJ; Lee SH; Park WS; Kim JH; Kim IS; Choi MJ; Ahn YK; Cho JG; Park JC; Cho DL; Kim H; Kang JC
    Korean J Intern Med; 2004 Dec; 19(4):220-9. PubMed ID: 15683110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study.
    Nunes GL; Abizaid AC; Theodoro MP; Brito FS; Caixeta A; da Silva LF; Mazzotti NG; Belló-Klein A; Clausell N
    Am Heart J; 2006 Nov; 152(5):914.e1-7. PubMed ID: 17070157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting.
    De Luca L; De Persio G; Minati M; Iacoboni C; Fedele F
    Am Heart J; 2005 Jun; 149(6):1135. PubMed ID: 15976799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
    Cho L; Marso SP; Bhatt DL; Topol EJ
    J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
    Hong MK; Mintz GS; Lee CW; Kim YH; Lee SW; Song JM; Han KH; Kang DH; Song JK; Kim JJ; Park SW; Park SJ
    Circulation; 2004 Feb; 109(7):881-6. PubMed ID: 14967732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.
    Dussaillant GR; Mintz GS; Pichard AD; Kent KM; Satler LF; Popma JJ; Wong SC; Leon MB
    J Am Coll Cardiol; 1995 Sep; 26(3):720-4. PubMed ID: 7642865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.